These are available under various brand names for treating endocrine problems
Bottom line: Theyre concerned about what will happen when people many in far greater need than me cant pay for their medication
Ongoing studies, such as the SOUL trial, are exploring the potential cardiovascular benefits of oral semaglutide in T2DM patients with established atherosclerotic cardiovascular disease and/or chronic kidney disease [50]
Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, Ruotolo G, Haupt A, Newgard CB, Duffin KL
When these foods reach the large intestine they feed beneficial gut bacteria, leading to the production of the SCFAs that trigger GLP-1 release
However, compounded GLP-1 medications are not identical to FDA-approved products